TARTAN-HF trial reveals simple heart-failure screening could help identify undiagnosed heart failure in diabetes: Our Bureau, Mumbai Wednesday, April 8, 2026, 12:15 Hrs [IST] The ...
Amgen announces positive phase 3 results for subcutaneous Tepezza in adults living with moderate-to-severe active thyroid eye disease: Thousand Oaks, California Wednesday, April 8 ...
InVera Medical receives US FDA 510(k) clearance for InVera Infusion Device, a novel non-thermal catheter for enhanced ...
Upsher-Smith introduces generic version of Ciprodex sterile Otic suspension: Maple Grove, Minnesota Upsher-Smith Laboratories, LLC (Upshe ...
Sanofi’s lunsekimig meets primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP: Paris Wednesday, April 8, 2026, 09:00 Hrs [IST] Phase 2 studie ...
Biggest opportunity lies in building global scale facilities as cos tap PLI, RDI incentives: Kiran Mazumdar-Shaw: Nandita Vijayasimha, Bengaluru Wednesday, April 8, 2026, 08:00 Hr ...
Experts assess how patent expiry of semaglutide is reshaping GLP-1 pricing and patient access: Shardul Nautiyal, Mumbai Wednesday, April 8, 2026, 08:00 Hrs [IST] India is experien ...
CBC–RIS partnership signals AI-led transformation for healthcare and pharma: Experts: Shardul Nautiyal, Mumbai Wednesday, April 8, 2026, 08:00 Hrs [IST] In a landmark move to st ...
DTAB not to pursue proposal to mandate free medicine from pharma cos as part of CSR: Gireesh Babu, New Delhi Wednesday, April 8, 2026, 08:00 Hrs [IST] The Drugs Technical Advisory ...
The AIOCD contends that these draft rules act as loopholes that allow e-pharmacies to bypass the stringent requirements of the Drugs and Cosmetics Act. The organization believes these digital pharmacy ...
DoP again tweaks RPTUAS guidelines to liberalise modalities of implementation: Gireesh Babu, New Delhi Wednesday, April 8, 2026, 08:00 Hrs [IST] The Department of Pharmaceuticals ...
US FDA issued a draft guidance for industry titled “New Clinical Investigation Exclusivity (3 years exclusivity) for drug products: Questions and answers.” The publication of this guidance has once ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results